Frontline therapy of multiple myeloma
نویسندگان
چکیده
منابع مشابه
Review Series MULTIPLE MYELOMA: FROM THE BENCH TO BEDSIDE Frontline therapy of multiple myeloma
Multiple myeloma (MM) accounts for 1% of all cancers and ;13% of all hematologic malignancies. Approximately 86 000 new cases of MM occur annually worldwide. This malignant neoplasm primarily affects elderly individuals with a median age at the time of diagnosis of ;70 years. Active MM is consistently preceded by precursor states of monoclonal gammopathy of undetermined significance and smolder...
متن کاملPosttransplantation maintenance therapy and optimal frontline therapy in myeloma.
One of the major efforts to improve the results of intensive therapy and autologous stem cell transplantation (ASCT) in multiple myeloma involves the integration of novel agents into the transplantation sequence. This can include their administration before, during, and after the transplantation procedure. Several phase 2 and 3 studies have evaluated the use of novel agents as part of induction...
متن کاملTreatment of Multiple Myeloma
Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue. La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours.
متن کاملMultiple Myeloma Update
This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate into the bone marrow. Aspects related to pathophysiology, clinical manifestations, laboratory, study and treatment are described. These pieces of information are necessary to accomplish a better ...
متن کاملInduction Therapy in Multiple Myeloma
Today, multiple myeloma (MM) can be defined as a heterogenous disease composed of different clinical conditions. The differences are a result of patient related factors (age, sex, comorbidity), disease related complications (renal failure, bone disease, neuropathy, throm‐ bosis) and biological characteristics (cytogenetics, lactate dehydrogenase level, plasma cell labelling index, beta2-microgl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2015
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2014-09-568915